Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromide (typically administered as potassium bromide) is one of the oldest known antiepileptic drugs, first introduced into clinical practice in 1857. It acts as a central nervous system depressant by increasing the seizure threshold. The mechanism of action involves bromide ions competing with chloride ions for transport through GABA-A receptor-associated chloride channels. Because bromide ions are more permeable than chloride ions through these channels, their entry into the neuron leads to membrane hyperpolarization, effectively reducing neuronal excitability and stabilizing the neuronal membrane. Although largely superseded by modern anticonvulsants due to its narrow therapeutic window and the risk of chronic toxicity (bromism), bromide remains a critical therapy for refractory pediatric epilepsy syndromes, most notably Dravet syndrome and West syndrome, particularly in regions like Europe and Japan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromide.